AI assistant

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Insight Molecular Diagnostics Inc. Director's Dealing 2015

Dec 31, 2015

34238_dirs_2015-12-31_46aa613a-99ea-41b1-9965-71a9580e8682.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: OncoCyte Corp (OCX)
CIK: 0001642380
Period of Report: 2015-12-30

Reporting Person: Redmond Cavan M. (Director)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Option to Purchase Common Stock	$3.16	2025-09-08	Common Stock (10000)		Direct

Footnotes

F1: Will become exercisable in four equal installments at the end of each calendar quarter based upon continued service on the board of directors from the date of grant.